Trial · NCT01260688
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) | 3 months | All patients were included in the analysis for 12-week PFS. | participants | NUMBER |
| SECONDARY | Number of Participants With Toxicities | Up to 30 days after last dose of study drugs | participants | NUMBER | |
| SECONDARY | Qualtiy of Life Assessment Number of Participants With a Score ≥2 on the Present Pain Intensity (PPI) Scale | After every cycle (median duration on study = 4 cycles) | Analysis was performed patients receiving single agent cediranib or combination of cediranib plus dasatinib. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number Who Experienced Study Medication Dose Intensity | Cycle 1 (an average of 28 days) | participant | NUMBER | |
| SECONDARY | Treatment Discontinuation | Cycle 1 (average of 28 days) | Analysis was performed on study participants enrolled on the trial assessing number of patients who discontinued treatment in cycle 1. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Treatment Discontinuation Due to Adverse Events (AEs) | Through study completion (median duration on study = 4 cycles) | participants | NUMBER | |
| SECONDARY | Non-AE Related Treatment Discontinuation | Through study completion (median duration on study = 4 cycles) | participants | NUMBER | |
| SECONDARY | Overall Response Rate | Duration of Study (median duration on study = 4 cycles) | months | MEDIAN | |
| SECONDARY | Treatment Related Deaths | Through study completion (median duration on study = 4 cycles) | In Arm II (Cediranib alone), 1 patient presented retroperitoneal hemorrhage (Grade 5). | participants | NUMBER |
| SECONDARY | Participants for Which Bone Biomarkers for Beta-C Telopeptide Was Reduced | Through study completion (median duration on study = 4 cycles) | Analysis was done on study participatns for which beta-C telopeptide was reduced. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Increased Alkaline Phosphatase BAP | Through study completion (median duration on study = 4 cycles) | participants | NUMBER | |
| SECONDARY | Dose Interruption Due to AEs | Through study completion (median duration on study = 4 cycles) | Analysis was performed on study participants assessing the number of participants with dose-interruptions due to adverse events. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Dose Reductions | Duration of Study (median duration on study = 4 cycles) | Analysis conducted on the number of participants with dose reductions in each arm of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Overall Response Rate | Duration of Study (median duration on study = 4 cycles) | Analysis of number of participants who experienced response rates of SD and PD. | percentage of participants | NUMBER |
| SECONDARY | Quality of Life Assessment Using Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire | Up to 16 weeks | Some participants (overall and post-baseline) did not complete the questionnaire or failed to answer more than 7 questions and could not be included in the analysis (a summary score could not be calculated). | units on a scale | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01260688/outcomes